Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Enzo Biochem (ENZ) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 308,291
  • Shares Outstanding, K 46,290
  • Annual Sales, $ 102,770 K
  • Annual Income, $ 45,290 K
  • 36-Month Beta 1.40
  • Price/Sales 2.96
  • Price/Cash Flow 0.00
  • Price/Book 3.44

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.27 +6.22%
on 01/31/17
6.96 -4.31%
on 02/06/17
-0.13 (-1.91%)
since 01/24/17
3-Month
6.27 +6.22%
on 01/31/17
7.51 -11.32%
on 12/09/16
-0.34 (-4.86%)
since 11/23/16
52-Week
4.00 +66.50%
on 03/04/16
7.51 -11.32%
on 12/09/16
+2.41 (+56.71%)
since 02/24/16

Most Recent Stories

More News
Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss

Seattle Genetics, Inc (SGEN) reported a loss of 39 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents and wider than the year-ago loss of 18 cents.

ENZ : 6.66 (+1.22%)
SGEN : 62.73 (-0.54%)
AGTC : 7.25 (-2.03%)
SNSS : 4.29 (+2.39%)
Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise

Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.

ENZ : 6.66 (+1.22%)
MDCO : 52.06 (+0.42%)
ALNY : 46.62 (+0.80%)
SNY : 42.70 (+0.45%)
Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View

GlaxoSmithKline plc (GSK)'s fourth quarter beat estimates but the outlook for 2017 was weak amid a potential entry of generics for Advair.

ENZ : 6.66 (+1.22%)
SCMP : 11.75 (+0.43%)
SNSS : 4.29 (+2.39%)
GSK : 41.56 (+0.17%)
Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.

Amgen Inc. (AMGN) announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis....

ENZ : 6.66 (+1.22%)
LLY : 82.87 (+0.39%)
AMGN : 174.56 (+0.32%)
GSK : 41.56 (+0.17%)
GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1

GW Pharmaceuticals plc (GWPH) reported first-quarter fiscal 2017 loss of 77 cents per share, much narrower than both the Zacks Consensus Estimate of a loss of $1.35 and the year-ago figure of 82 cents....

ENZ : 6.66 (+1.22%)
LLY : 82.87 (+0.39%)
GWPH : 123.74 (-0.45%)
GSK : 41.56 (+0.17%)
Mallinckrodt (MNK) Tops on Earnings in Transition Quarter

Mallinckrodt Public Limited Company (MNK) reported positive results for the transition quarter (Oct 1, to Dec 30, 2016) beating both sales and earnings expectations.

ENZ : 6.66 (+1.22%)
SCMP : 11.75 (+0.43%)
MNK : 53.38 (-2.00%)
SNSS : 4.29 (+2.39%)
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3

Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.

ENZ : 6.66 (+1.22%)
RDY : 43.24 (-0.46%)
TEVA : 35.38 (-1.23%)
SNSS : 4.29 (+2.39%)
Novo Nordisk (NVO) Misses Q4 Earnings, Revenues Down Y/Y

Novo Nordisk A/S (NVO) reported fourth-quarter 2016 earnings of 50 cents per American Depository Receipt (ADR), missing the Zacks Consensus Estimate of 52 cents by 3.8%.

ENZ : 6.66 (+1.22%)
ANIK : 49.75 (+0.36%)
SNSS : 4.29 (+2.39%)
AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales

AstraZeneca PLC (AZN) reported fourth-quarter 2016 core earnings of $1.21 per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 51 cents. Core earnings also rose 9% year...

ENZ : 6.66 (+1.22%)
ANIK : 49.75 (+0.36%)
AZN : 29.35 (-0.54%)
LLY : 82.87 (+0.39%)
BioMarin's Hemophilia Candidate Included in PRIME Initiative

BioMarin Pharmaceutical Inc. (BMRN) announced that BMN 270, being evaluated for the treatment for severe hemophilia A, has been granted access to Priority Medicines (PRIME), a regulatory initiative by...

ENZ : 6.66 (+1.22%)
ANIK : 49.75 (+0.36%)
BMRN : 87.51 (-1.99%)
SNSS : 4.29 (+2.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo...

See More

Support & Resistance

2nd Resistance Point 6.77
1st Resistance Point 6.72
Last Price 6.66
1st Support Level 6.56
2nd Support Level 6.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.